

Date: December 16, 2024

BSE Limited

P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Script Code: 543904

Symbol: MANKIND

Dear Sir/ Madam,

Subject: Qualified Institutions Placement of Equity Shares of face value of ₹1 each (the “Equity Shares”) by Mankind Pharma Limited (the “Company”) under the provisions of Chapter VI of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the “SEBI ICDR Regulations”), and Sections 42 of the Companies Act, 2013 (including the rules made thereunder), as amended (the “Issue”)

We wish to inform you that pursuant to the approval of the Board of Directors of the Company at its meeting held on May 15, 2024, and approval of the shareholders of the Company by way of a special resolution passed through postal ballot on June 17, 2024, the Fund Raising Committee of the Board of the Company, in its meeting held today i.e. December 16, 2024, has *inter alia* considered and approved the following:

1. Raising of funds aggregating up to ₹ 3,000 crores (Indian Rupees Three Thousand Crores only) by way of Qualified Institutions Placement (“QIP”) under applicable laws, including the Companies Act, 2013 read with the rules notified thereunder and Chapter VI of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, by way of issuance of such number of equity shares having a face value of ₹ 1 each of the Company;
2. Approval and authorization of the opening date of the Issue today i.e. December 16, 2024;
3. The Floor price for the Issue, being ₹ 2,616.55/- per Equity Share (“Floor Price”), based on the pricing formula as prescribed under the SEBI ICDR Regulations;
4. Adopted the preliminary placement document dated December 16, 2024 and the application form dated December 16, 2024 in connection with the Issue; and

A certified copy of the resolution passed by the Fund Raising Committee authorising the opening of the Issue and fixing the Floor Price and Relevant Date is enclosed for your information and records.

MANKIND PHARMA LIMITED

Regd. Office : 208, Okhla Ind. Estate, Phase - 3, New Delhi-110020 • Ph. : 011-46846700, 47476600
CIN No. L74899DL1991 PLC044843 • E-mail : contact@mankindpharma.com • www.mankindpharma.com

The Fund Raising Committee of Directors of the Company has fixed the 'relevant date' for the purpose of the Issue, in terms of Regulation 171(b)(i) of the SEBI ICDR Regulations, as December 16, 2024, and accordingly the floor price i.e. ₹ 2,616.55/- per Equity Share in respect of the Issue has been determined, based on the pricing formula as prescribed under Regulation 176(1) of the SEBI ICDR Regulations.

Further, pursuant to Regulation 176(1) of the SEBI ICDR Regulations and in accordance with the approval of the Shareholders accorded through a special resolution on June 17, 2024, the Fund Raising Committee of Directors of the Company may at its discretion offer a discount of not more than 5% on the floor price so calculated for the Issue. The Issue Price will be determined by the Company in consultation with the book running lead managers appointed in relation to the Issue.

The meeting of the Fund Raising Committee of Directors of the Company commenced at 6:35 pm IST and concluded at 11:20 pm IST.

The information in the above intimation is also being uploaded on the website of the Company at www.mankindpharma.com.

You are requested to kindly take the same on record.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

Ashish Mittal
Company Secretary and Compliance Officer

Encl.: as above

CERTIFIED TRUE COPY OF THE RESOLUTION PASSED BY THE FUND RAISING COMMITTEE OF THE DIRECTORS OF THE MANKIND PHARMA LIMITED HELD ON DECEMBER 16, 2024

FIXATION OF THE FLOOR PRICE FOR THE QUALIFIED INSTITUTIONS PLACEMENT (“QIP ”)

“**RESOLVED THAT** in respect of the proposed QIP of the Company, in terms of the Chapter VI of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 and Section 42 of the Companies Act, 2013, read with Rule 14 of the Companies (Prospectus and Allotment of Securities) Rules, 2014, read with applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in accordance with any other applicable laws if any, the floor price of ₹ 2,616.55 per Equity Share (“Floor Price”), as calculated based on the pricing formula prescribed under Regulation 176(1) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (“SEBI ICDR Regulations”) and based on the certificate received from M/s. S. R. Batliboi & Co. LLP, Chartered Accountants, Joint Statutory Auditors of the Company, be and is hereby approved.

RESOLVED FURTHER THAT in respect of the Issue and in accordance with the proviso to Regulation 176(1) of the SEBI ICDR Regulations, the Company may offer a discount of not more than 5% on the Floor Price calculated for the Issue, in accordance with applicable law and the approval of the shareholders of the Company by way of a postal ballot on July 17, 2024.

RESOLVED FURTHER THAT Mr. Ramesh Juneja, Chairman & Whole Time Director, Mr. Rajeev Juneja, Vice Chairman & Managing Director, Mr. Sheetal Arora, Chief Executive Officer & Whole Time Director, Mr. Prem Kumar Arora, Director-FHA, Mr. Arjun Juneja, Chief Operating Officer, Mr. Chanakya Juneja, Director-Technology, Mr. Ashutosh Dhawan, Chief Financial Officer of the Company and Mr. Ashish Mittal Company Secretary & Compliance Officer of the Company be and are hereby severally authorized by the Fund Raising Committee to do all such acts, deeds, matters and things, as may be required to give effect to the above resolutions and to do such filings intimations and disclosures with the Stock Exchanges or any other regulatory or statutory authorities in accordance with applicable laws.

RESOLVED FURTHER THAT a copy of the above resolution, certified to be true by any of the Directors of the Company or the Company Secretary of the Company, be forwarded to the authorities concerned for necessary action.”

FOR MANKIND PHARMA LIMITED

**ASHISH MITTAL
COMPANY SECRETARY AND COMPLIANCE OFFICER**

**DATE: 16/12/2024
PLACE: NEW DELHI**

MANKIND PHARMA LIMITED

Regd. Office : 208, Okhla Ind. Estate, Phase - 3, New Delhi-110020 • Ph. : 011-46846700, 47476600
CIN No. L74899DL1991 PLC044843 • E-mail : contact@mankindpharma.com • www.mankindpharma.com

CERTIFIED TRUE COPY OF THE RESOLUTION PASSED BY THE FUND RAISING COMMITTEE OF THE DIRECTORS OF THE MANKIND PHARMA LIMITED HELD ON DECEMBER 16, 2024

APPROVAL OF ISSUE OPENING AND RELEVANT DATE

“**RESOLVED THAT** subsequent to the resolution passed by the board of directors of the Company at its meeting held on May 15, 2024 and the special resolution passed by the shareholders of the Company by way of postal ballot on June 17, 2024 under Sections 42 other applicable provisions of the Companies Act, 2013 (“Act”) read with the applicable provisions of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (“SEBI ICDR Regulations”), the issue of equity shares of face value of ₹ 1 each of the Company to eligible qualified institutional buyers (“QIBs”) in terms of the Chapter VI of the SEBI ICDR Regulations and Section 42 and any other applicable provisions of the Act read with Rule 14 of the Companies (Prospectus and Allotment of Securities) Rules, 2014 and the provisions of all other applicable laws, rules, regulations, guidelines, circulars and notifications, be opened today, i.e. December 16, 2024 for receiving bids in connection with the Issue.

RESOLVED FURTHER THAT in respect of the Issue, the relevant date, in terms of Regulation 171(b)(i) of SEBI ICDR Regulations, for determination of the minimum price at which the Equity Shares shall be issued pursuant to the Issue, shall be the date of this resolution, i.e., December 16, 2024.

RESOLVED FURTHER THAT Mr. Ramesh Juneja, Chairman & Whole Time Director, Mr. Rajeev Juneja, Vice Chairman & Managing Director, Mr. Sheetal Arora, Chief Executive Officer & Whole Time Director, Mr. Prem Kumar Arora, Director-FHA, Mr. Arjun Juneja, Chief Operating Officer, Mr. Chanakya Juneja, Director-Technology, Mr. Ashutosh Dhawan, Chief Financial Officer of the Company and Mr. Ashish Mittal Company Secretary & Compliance Officer of the Company be and are hereby severally authorized by the Fund Raising Committee to do all such acts, deeds, matters and things, as may be required to give effect to the above resolutions and to do such filings intimations and disclosures with BSE Limited and National Stock Exchange of India Limited or any other regulatory or statutory authorities in accordance with applicable laws.

RESOLVED FURTHER THAT a copy of the above resolution, certified to be true by any of the Directors of the Company or the Company Secretary of the Company, be forwarded to the authorities concerned for necessary action.”

FOR MANKIND PHARMA LIMITED

ASHISH MITTAL
COMPANY SECRETARY AND COMPLIANCE OFFICER

DATE: 16/12/2024
PLACE: NEW DELHI